# Precision Neuroscience Secures $250M in Series D Funding Brain-computer interface company reaches $1bn valuation - **Source:** [The Next Web](https://brifing.si/source/afe24b20-b275-4c19-b9a6-8bb3c8babae7) - **Published:** 2026-09-24 - **Topic:** [Data & AI](https://brifing.si/c/data-ai) - **Original article:** - **On Brifing:** https://brifing.si/s/e8585a6f-d888-4e89-a7a6-5cd6ccb8e301 ## Funding Round Details Precision Neuroscience announced a $250 million Series D funding round, valuing the company at over $1 billion. The investment was led by Bill Ackman’s Pershing Square, the Ackman Oxman Institute, and an unnamed life sciences fund. Pershing Square and the institute contributed $42.5 million. Since its inception in 2021, Precision has raised a total of $430 million. ## Investor Background Bill Ackman, co-founder of the Ackman Oxman Institute, highlighted Precision’s less invasive approach as a key factor in his investment. The institute, a brain research center in Manhattan, made Precision its first investment. Ackman emphasized the potential for brain recovery from neurological injuries, aligning with Precision’s mission. ## Notable Participants The funding round attracted significant investors, including Duquesne Family Office, B Capital, ARK Invest, and Invus. Other participants were Mubadala Capital, Mirae Asset Capital, Korea Investment Partners, Hitachi Ventures, and JSL Health Capital. ARK Invest, also a backer of Neuralink, added credibility to Precision’s vision. ## Technology Comparison Precision’s Layer 7 technology features a thin film with 1,024 electrodes placed on the brain’s surface, contrasting with Neuralink’s internal electrode placement. Experts note that surface devices reduce risks of infection and scarring. However, internal electrodes can read single neurons, potentially offering higher accuracy. ## Founder Connections Benjamin Rapoport, one of Precision’s founders, was also a co-founder of Neuralink. This connection underscores the competitive landscape in brain-computer interface development. Rapoport’s expertise bridges both companies, highlighting the industry’s collaborative yet competitive nature. ## Regulatory Milestones The FDA cleared Precision’s Layer 7 for up to 30 days of use in April 2025. The device is part of a wireless implant still in development. CEO Michael Mager stated that the new funding will support efforts to gain approval for permanent implants, a process expected to take several years. ## Clinical Progress Precision has conducted over 100 procedures across 18 medical centers and partnered with Medtronic. The company manufactures its electrode arrays in Texas and is preparing an early feasibility study for its fully implantable system, targeting patients with severe paralysis. ## Industry Context Over $2 billion has been invested in brain-computer interface companies in the past 18 months. Competitors like Paradromics and Chinese firms have made significant strides, with Paradromics implanting its first brain chip in June. Researchers continue to explore AI-driven solutions for paralysis recovery. ## Sources covering this story - https://thenextweb.com/news/precision-neuroscience-250m-series-d-1bn-valuation-ackman — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._